Visit Patient Landing Page

You are now leaving our website.

If you click “Continue” below, you will leave the current site and be taken to a site maintained by a third party that is solely responsible for its content. Amgen provides this link as a service to website visitors. Amgen is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

Continue Cancel
Hypothetical male with high ldl-c
Hypothetical male with high ldl-c
Based on the 2022 ACC Expert Consensus Decision Pathway recommendation

Your patients with ASCVD at very high risk for another CV event should have an LDL-C level < 55 mg/dL1

expert-recommend-ldlc
more-than-90-percent

Identify your patients’ risk status

Common factors can put your patients with ASCVD at very high risk for another CV event. Identifying their risk status may help you optimize LDL-C management.1
Assess Patient Risk Status

Based on the 2018 AHA/ACC Multisociety cholesterol treatment guidelines1,3

Your ASCVD patients are at very high risk if they have:
1 major event icon
1 Major ASCVD EVENT + Multiple High-Risk ConditionS
(such as: age ≥ 65 years, diabetes, hypertension)
Multiple major ASCVD events icon
Multiple major
ascvd events
(including: prior history of MI, prior stroke, symptomatic PAD, acute coronary syndrome within 12 months)

2022 ACC Expert Consensus Decision Pathway recommendation for ASCVD patients at very high risk:1,*

Consider initiating nonstatin therapies
after evaluating the following:
  • Statin-associated side effects
  • Escalating to high-intensity statins if not already taking
  • Optimizing lifestyle
  • Adherence to guideline-recommended statin therapy
  • Risk factor control
Down arrow icon

LDL-C < 55 mg/dL

≥ 50% LDL-C

REDUCTION FROM BASELINE

*Very high-risk patients have a history of multiple major ASCVD events or 1 major ASCVD event and multiple high-risk conditions, as previously defined in the 2018 AHA/ACC Multisociety cholesterol management guideline.1,3

PAD = peripheral artery disease.

References: 1. Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2022 ACC Expert Consensus Decision Pathway on the role of nonstatin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2022;80:1366-1418. 2. Muntner P, Orroth KK, Mues KE, et al. Evaluating a simple approach to identify adults meeting the 2018 AHA/ACC cholesterol guideline definition of very high risk for atherosclerotic cardiovascular disease. Cardiovasc Drugs Ther. 2022;36:475-481. 3. Grundy SM, Stone SJ, Baily AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2018;73:e285-e350.